Peekcell develops a non-invasive cancer detection solution that analyzes urine biomarkers using an artificial intelligence algorithm to provide accurate risk assessments. This technology addresses the challenge of low participation rates in traditional cancer screenings by offering a painless, accessible, and quick alternative for early-stage detection of gynecological cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Participation rates in traditional gynecological cancer screenings are low due to discomfort, accessibility issues, and time constraints. This leads to delayed detection and poorer outcomes for women, as early-stage detection significantly improves survival rates.
Solution
Peekcell offers a non-invasive cancer detection solution based on urine biomarker analysis and artificial intelligence. The test is designed to be simple, accessible, and quick, enabling early-stage detection of gynecological cancers. Patients can collect a urine sample at home or in a clinic, eliminating the need for invasive procedures or specialized healthcare professional assistance during sample collection. The sample is then analyzed for specific biomarkers, and an AI algorithm calculates a risk score to aid practitioners in making informed decisions based on the patient's profile and other relevant information.
Target Audience
The primary target audience includes women of all ages seeking convenient and accessible cancer screening, as well as healthcare professionals looking for innovative diagnostic tools to improve early detection rates.
Features
- Non-invasive urine sample collection, eliminating discomfort and increasing accessibility
- Analysis of early and specific biomarker signatures in urine
- Proprietary artificial intelligence algorithm for risk score calculation
- Rapid processing time from sample collection to results
- Suitable for women of all ages
- Enables sample shipment for remote testing